All 1 Debates between Simon Opher and Esther McVey

Medicines and Healthcare Products Regulatory Agency

Debate between Simon Opher and Esther McVey
Tuesday 17th November 2026

(1 day, 9 hours ago)

Westminster Hall
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.

Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Simon Opher Portrait Dr Opher
- Hansard - -

That is indeed an enormous problem. They say that about 2.5 million people are trying to get off antidepressants, but patients are not informed of these issues.

Esther McVey Portrait Esther McVey
- Hansard - - - Excerpts

The hon. Member is making a significant speech. One of my constituents on a selective serotonin reuptake inhibitor antidepressant committed suicide. Does he agree with me about the delays at the MHRA? There was significant evidence over a prolonged period of time that people on antidepressants could commit suicide when they come off, and yet nothing was done.

Simon Opher Portrait Dr Opher
- Hansard - -

That is absolutely true. There are higher risks of suicide when someone starts antidepressants and when they try to come off them, and patients are rarely informed about that. That is why we want more information from the MHRA in the pill packets.

Although we do not really know how antidepressants work, one accepted effect is that they dull emotions, which is called emotional blunting or numbness. That may be welcome for some, but for others it is profoundly distressing. Patient information leaflets might list effects such as apathy, indifference and lack of emotion or attachment, but patients have contacted the APPG to say that those terms do not convey the blunting of positive feelings as well as the negative ones.

One male patient in his 60s recently described the emotional blunting effect of his long-term antidepressants as

“suppressed love, joy, optimism, hope and creativity”.

He therefore decided to stop taking them, but like many others he suffered distressing and protracted withdrawal symptoms, with little support from his GP.

There is now another MHRA review into how well risks associated with withdrawals from antidepressants are communicated. Research suggests that between 34% and 50% of patients who try to come off them, as the right hon. Member for Tatton said, may experience quite severe withdrawal effects. Some 15% of patients who are long-term users—meaning they have used the drugs for more than a year—are likely to have severe withdrawal effects, and yet many of the drug companies do not accept that these drugs are addictive.

Since 2022, the National Institute for Health and Care Excellence has recognised that, for the patients most at risk of experiencing withdrawal, dosages need to be reduced in a slow, stepwise fashion called hyperbolic tapering. We call on the MHRA to urgently consider the need for licensing smaller doses of existing antidepressant drugs to enable that safer deprescribing. Currently, liquid antidepressants can be used, but they are off-label and incredibly expensive, which disincentivises GPs from prescribing them. It is also difficult to dilute them and get the correct dosage. We therefore need the MHRA to force drug companies to make smaller doses of tablets.

This is a tricky situation because antidepressants are licensed to treat indications such as depression, not for deprescribing. That means that very small doses of antidepressants cannot currently be created in tablet form under licence. Compounding pharmacies can make up little tablets, but they are unlicensed and cannot be routinely prescribed. A solution is urgently needed for licensing small doses of these drugs. Drug manufacturers should also be required to provide doses suitable for deprescribing for all new psychotropic drugs that will be licensed in the future. I hope the MHRA will seriously consider and act on those points.

As an addendum, I would be interested in the Minister’s view on the role of the MHRA in the regulation of AI in the NHS. As chair of the all-party parliamentary health group, I am chairing a meeting later to discuss the 44 recommendations that have recently been put forward.